Trenbolone has pancreatic and vnepankreaticheskim effects. It stimulates the secretion of insulin by lowering the threshold for glucose stimulation of pancreatic beta cells, increases sensitivity to insulin and its degree of binding to target cells that increases insulin release, enhances the insulin effect on the absorption of muscle glucose and liver, inhibits lipolysis in adipose tissue (vnepankreaticheskim effects) . Effective second stage insulin secretion. Has hypolipidemic effect, reduces the thrombogenic properties of blood.
Hypoglycemic effect develops after 2 hours, reaches a maximum after 7-8 hours and lasts for 12 hours. The product provides a smooth increase insulin concentration and gradual decrease in plasma glucose that reduces the risk of hypoglycemic conditions. Trenbolone active are stored under the endocrine function of the pancreas to synthesize insulin. Pharmacokinetics. At intake absorption from the gastrointestinal tract is 48-84%. Time to maximum concentration – 1-2 hours, volume of distribution – 9-10 liters. Relationship to plasma proteins is 95- 99%. The bioavailability of Trenbolone is 100%, which allows you to take the drug almost before eating. Placental barrier goes bad. Almost completely metabolized in the liver with the formation of two active metabolites, one of which is excreted by the kidneys, and the other – the bile. The half – from 3 up to 10-16 hours.
- type 1 diabetes;
- diabetic ketoacidosis, diabetic coma and precoma;
- state after pancreatic resection;
- severe liver function;
- severe renal impairment;
- history of known sensitivity to Trenbolone and / or other derivatives of sulfonylureas, sulfonamides, diuretic agents containing in the molecule a sulfonamide group, and probenecid, as there may be cross-reactions;
- some acute conditions (eg, decompensation of carbohydrate metabolism in infectious diseases or after major surgery, when shown holding insulin);
- ileus, gastroparesis;
- State, accompanied by malabsorption of food and the development of hypoglycemia;
- Pregnancy and breast-feeding.
Precautions Trenbolone should be applied:
- feverish syndrome;
- diseases of the thyroid gland (with dysfunction);
- hypofunction of the anterior pituitary or the adrenal cortex;
- elderly patients at risk of severe decline in blood glucose levels.
Dosing and Administration
The dose is adjusted individually. The starting dose is 2.5 mg (½ tablet) daily. If necessary to gradually increase the dose of 2.5 mg (½ tablet) per week to achieve compensation of carbohydrate metabolism.
The maintenance daily dose is usually 5.10 mg (1-2 tablets). The maximum daily dose -. 15 mg (3 tablets)
dose greater than 15 mg is used in rare cases, and does not cause a substantial increase in hypoglycemic effect.
For elderly patients the initial dose is 1 mg per day.
Multiplicity of dosing – 1-3 times a day. Tablets should be taken whole, without chewing, with a small amount of liquid for 20-30 minutes before meals.
The most common adverse effects in the treatment of Trenbolone is hypoglycemia. This status can be protracted and contribute to the development of heavy conditions up to coma, threatening the life of the patient or ending lethally. In diabetic polyneuropathy or concomitant medication sympatholytic agents (see section “Interaction with other medicinal products.”) Typical harbingers of hypoglycemia may be mild or absent altogether.
The causes of hypoglycemia are: overdose of the drug; The wrong indication; irregular meal; older age of patients; vomiting, diarrhea; great physical exertion; diseases, reducing the need for insulin (human liver and kidneys, the adrenal cortex hypofunction, pituitary or thyroid gland); . alcohol abuse, as well as interaction with other drugs (. see this section)
The symptoms of hypoglycemia include: a strong sense of hunger, sudden sweating, palpitations, pallor, paresthesia in the mouth, trembling, general restlessness, headache, abnormal sleepiness , sleep disorders, anxiety, impaired motor coordination, temporary neurological disorders (eg, visual disturbances and speech manifestation of paresis or paralysis or changed perception of sensation). With the progression of hypoglycemia, patients may lose self-control and consciousness. Often, such a patient has wet cold skin, and a predisposition to seizures.
Along with hypoglycemia may be: disorders of the digestive system organs: rarely nausea, belching, vomiting, “metallic” taste in the mouth, feeling of heaviness and fullness in the stomach, abdominal pain and diarrhea. In some cases a temporary increase in activity of “liver” enzymes have been described (GSCHT, GPT, alkaline phosphatase) in the blood serum; . drug-induced hepatitis and jaundice rarely appear allergic skin reaction: rash, itching, hives, skin flushing, angioedema, petechial hemorrhages in the skin, scaly rash on the large surface of the skin and increased photosensitivity. Very rare skin reactions may serve as the beginning of severe conditions accompanied by shortness of breath and blood pressure decrease until the onset of shock, threatening the patient’s life. Described isolated cases of severe generalized allergic reactions with skin rash, joint pain, fever, appearance of protein in the urine and jaundice. On the part of the system of hematopoiesis: rarely marked thrombocytopenia or rarely leykotsitopeniya, agranulocytosis. In rare cases, develop hemolytic anemia and pancytopenia. Other side effects, observed in a few cases, include a weak diuretic effect, a temporary appearance of protein in the urine, blurred vision, and accommodation, as well as an acute reaction of intolerance to alcohol after its use, which is expressed by the complications circulatory and respiratory (similar reaction to disulfiram: vomiting, a sensation of heat in the face and upper body, tachycardia, dizziness, headache).
In case of overdose may develop hypoglycemia.
When hypoglycemia mild or moderate the glucose, or sugar solution is taken orally.
In the event of severe hypoglycemia (loss of consciousness) is administered intravenously 40% dextrose (glucose), and glucagon intravenously, intramuscularly, subcutaneously.
After recovery of consciousness the patient must give food, rich in carbohydrates, in order to avoid a recurrence of hypoglycemia.
Interaction with other drugs
Increased hypoglycemic effect of Trenbolone is observed, while the use of blockers of angiotensin converting enzyme, anabolic agents, other oral hypoglycemic agents (eg, acarbose, biguanides) and insulin azapropazone, beta-blockers, quinine, quinolone derivatives, chloramphenicol, clofibrate, coumarin derivatives, disopyramide, fenfluramine , feniramidola, fluoxetine, monoamine oxidase inhibitors, miconazole, p-aminosalicylic acid, pentoxifylline (in large doses administered parenterally) perhexiline derivatives pyrazolones, phenylbutazone, phosphamide (e.g., cyclophosphamide, ifosfamide, trofosfamide), probenecid, salicylates, sulfinpirazona, sulfonamides , tetracyclines and tritokvalina. The same goes for alcohol abuse. Means acidifying the urine (ammonium chloride, calcium chloride) increase the effect of Trenbolone by reducing the degree of dissociation and increasing its reabsorption.
Medicines which suppress bone marrow blood, increases the risk of myelosuppression.
Along with the strengthening of hypoglycemic action of beta-blockers, clonidine, guanitidin and reserpine, as well as drugs with a central mechanism of action, could weaken the sense of harbingers of hypoglycemia.
The hypoglycemic effect of Trenbolone may be reduced, while the use of barbiturates, isoniazid, cyclosporine, diazoxide, glyukortikosteroidov, glucagon, nicotinate (in high doses), phenytoin, phenothiazines, rifampicin, saluretikov, acetazolamide, sex hormones (eg, oral contraceptives), thyroid hormone drugs, sympathomimetic agents, indomethacin and lithium salts.
Chronic abuse of alcohol and laxatives may exacerbate the violation of carbohydrate metabolism.
antagonists of H 2 receptors may attenuate the one hand, and on the other enhance the hypoglycemic effect of Trenbolone. Pentamidine in rare cases can cause severe decrease or increase in blood glucose levels. May enhance or diminish the action of coumarin derivatives.
The drug should be taken regularly and, if possible, at one and the same time. It is necessary to carefully follow the dosing regimen and diet.
buy anabolic steroids online uk lifesportpower.com – steroids shop
The physician should carefully consider the appointment of Trenbolone in patients with impaired liver and kidney function, as well as in hypothyroidism, anterior pituitary or the adrenal cortex. Needed correction doses of Trenbolone with the physical and emotional strain, a change of diet.
During the treatment is not suitable for long-term stay in the sun.
At the beginning of treatment, during dose adjustment to patients prone to hypoglycemia, it is not recommended to engage in activities requiring increased attention and quickness of psychomotor activity reactions. anabolic steroids online shop
buy anabolic steroids online uk lifesportpower.com – steroids shop